Diabetes, Heart and Cardiovascular Diseases News Chronicle.  Diabetes, Cardiovascular and Heart Diseases
 Article 83
    Published on November 22, 2016


Statin Usage Reduces Cardiovascular Risk

Previous studies show that individual with diabetes is at greater risk of cardiovascular disease and usage of statin drugs reduces risk to cardiovascular disease. Researchers analyzed 215,193 diabetes patients and found that just 38 percent of patients are using statin drugs to prevent cardiovascular disease (CVD) and there was 57 percent practice level variation. One guideline suggests diabetes patients between 40 to 75 years with LDL cholesterol possible target of less than 70mg/dL. The American Diabetes Association (ADA) says diabetes patient with over 40 years should take statin therapy irrespective of LDL cholesterol levels and cardiovascular disease (CVD). Senior author of the study is Dr. Salim Virani, associate professor at Baylor College of Medicine, Houston and the research letter was published in the Journal of the American College of Cardiology.




       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Benefits With Statins Usage
2. Usage Of Statins Protects Diabetic Macular Edema DME
3. DPP-4 Inhibitor Linagliptin Tradjenta Prevents Cardiovascular Disease (CVD)
4. Cardiovascular Exercise Benefits With Interval Exercise training
5. Study On Wearable Technology Devices

 

Statins : Atheroma patches are small fatty lumps developed within the lining of blood vessels and blocks flow of blood. Blood flow blockage increases risks of heart attack and stroke. Cholesterol is one factor in the development of atheroma. Statins (also known as HMG-CoA reductase inhibitors) are class of drugs to lower lipids such as cholesterol. Studies show that high cholesterol levels in the bloodstream can be reduced in some individuals (about 25 to 35 percent) with the usage of statins class drugs.

Chances of side effects are rare but some of them are

  • Muscle pains or weakness
  • An enhanced risk of diabetes
  • Stomach upset
  • A headache
  • Sickness feeling
  • Rare chances of kidney failure
  • Rare chances of severe muscle damages

Some of the statin drugs in the market are

  • Simvastatin (Zocor)
  • Lovastatin (Mevacor, Altoprev)
  • Rosuvastatin (Crestor)
  • Pravastatin (Pravachol)
  • Atorvastatin (Lipitor)
  • Fluvastatin (Lescol)
  • Pitavastatin (Livalo)

Statin therapy is one measure to reduce risk to the development of cardiovascular diseases (CVD). Other measures are

  • Healthy diet
  • No smoking
  • Limiting alcohol intake
  • Physical exercise and no sedentary lifestyle
  • Taking aspirin tablet daily
  • Keeping blood pressure level under control
  • Reducing weight and BMI (less than 40 inches in men and less than 35 inches in women)

 

Phase 2 Trials of Sotagliflozin Diabetes Drug

Results of phase 2 study on the sotagliflozin drug from Lexicon Pharmaceuticals to treat type 1 diabetes (T1D) were positive. Results show a significant decline in blood sugar levels and enhanced drug safety during 12 week study period. Glucose levels in our body were controlled by two proteins, SGLT1 and SGLT2. Sotagliflozin is an oral drug that prevents both proteins. Sotagliflozin drug was joint efforts of Lexicon Pharmaceuticals and Sanofi SA. The phase 2 trials were conducted to select the sotagliflozin drug dosage for the phase 3 trials.




       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. SGLT1 and SGLT2 Inhibitor Sotagliflozin Drug Trials
2. About Whoop Wearable Device
3. Wristbands, Headbands, Skin Patches And Wearable Devices From Eccrine Systems
4. About Beat2Phone Wearable Device To Check Heart Health
5. Thim Wearable Device For Better Sleep

 

 

About Gal3 Galectin-3 Protein

A study done by researchers from the University of California-San Diego on obese and diabetic mice shows high levels of macrophages (a type of immune cell) in the fat tissues increases chronic inflammation and insulin resistance in liver, muscle and fat cells. Gal3 or galectin-3 is a signaling protein secreted by macrophages immune cells. The produced galectin-3 protein attracts more macrophages into fat tissues and a further increase in galectin-3 protein. Researchers say 40 percent of the cells in overweight individuals (and mice) are of type macrophages. Researchers also observed that blocking Gal3 protein improves insulin sensitivity. Senior author of the study is Prof Jerrold Olefsky. The study was published in the journal Cell.




       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Less Protein Food Content Increases Insulin Sensitivity
2. About T-Cells And c-Rel Protein
3. Access Crosby Wearable Fitness Tracking Products From Michael Kors
4. Activity Trackers And Wearable Devices From Alcatel
5. Personalized Diet And Fitness Device & App From STYR Labs

 

 

 

Site maps

Site map 1   Site map 2   Site map 3   Site map 4


The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.